Biopharma AI
By
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
Can Cedars-Sinai’s CS Connect Revolutionize Virtual Care? 42,000 Patients Served, AI Outperforms Doctors in 77% of Cases, K Health Partnership Sets New Standard
Key Takeaways: AI helping doctors focus on care, not paperworkCedars-Sinai launched CS Connect to improve access to care…
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape Chronic Disease Care in China’s Digital Health Boom?
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
